• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia
    • Books
    • eBooks
    • ABPN SA Courses
    • Social Work Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
    • Psychiatry News Videos
    • Medication Guide Videos
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
    • Psychotherapy and Social Work
  • FAQs
  • Med Fact Book App
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Is Modafinil an Effective Alternative for the Treatment of ADHD?

Is Modafinil an Effective Alternative for the Treatment of ADHD?

September 1, 2017
Ariana Ayón Verduzco, PharmD candidate (2018)
From The Carlat Child Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Ariana Ayón Verduzco, PharmD candidate (2018) Ms. Verduzco has disclosed that she has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Review of: Wang SM et al, J Psychiatr Res 2017;84:292–300.

Modafinil (Provigil) is FDA-approved for narcolepsy, obstructive sleep apnea, and shift work sleep disorder, but not for ADHD. Given that it has some of the same stimulating properties of psychostimulants, it should theoretically be effective. Wang and colleagues identified five randomized placebo-controlled trials testing modafinil for the treatment of ADHD in children and adolescents, and performed a meta-analysis of this data.

Of the 927 participants in these studies, 640 were randomly assigned to modafinil (doses ranged from 170–425 mg/day), and 287 were assigned to placebo. All five RCTs were short-term studies (all < 9 weeks). Patients on modafinil showed more improvement on ADHD scores than patients on placebo, with a standard mean difference vs placebo of -0.77 and -0.71 for the ADHD-RS-IV home and school versions, respectively. The standard mean difference is also known as the effect size, and this effect size is moderate to large. (For perspective, in previous meta-analyses, effect sizes for stimulants have been in the 0.6–0.8 range.) Modafinil patients experienced more insomnia and decreased appetite. Only four cases of serious adverse events (Stevens-Johnson syndrome, duodenitis, and two cases of dehydration) were reported in the modafinil group.

CCPR’s take
Modafinil appears to work about as well as stimulants for children and adolescents with ADHD. It is a good off-label option for kids who don’t respond or don’t tolerate stimulants. Just be aware that there is a small (likely very small) risk of Stevens-Johnson syndrome.
Child Psychiatry
KEYWORDS adhd child-psychiatry research-update
    Ariana Ayón Verduzco, PharmD candidate (2018)

    More from this author
    www.thecarlatreport.com
    Issue Date: September 1, 2017
    SUBSCRIBE NOW
    Table Of Contents
    Take The CME Post-Test for ADHD in Children and Adolescents, CCPR, September/October 2017
    Choosing Medications for ADHD
    Is Modafinil an Effective Alternative for the Treatment of ADHD?
    Can Strattera Improve Reading Skills in Children With Dyslexia?
    Understanding Tantrums in Autism Spectrum Disorder
    New Editor-in-Chief, Joshua D. Feder!
    An Integrative Approach to Attention Deficit Hyperactivity Disorder
    Official 2017 Carlat ADHD Pediatric Stimulant Comparison Table
    DOWNLOAD NOW
    Featured Book
    • PB4e_Cover2.png

      Psychiatry Practice Boosters, Fourth Edition (2023)

      Teaches you the key points of 63 of the most clinically relevant studies in psychiatry.
      READ MORE
    Featured Video
    • KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg
      General Psychiatry

      KarXT (Cobenfy): The Breakthrough Antipsychotic That Could Change Everything

      Read More
    Featured Podcast
    • shutterstock_2622607431.jpg
      General Psychiatry

      Should You Test MTHFR?

      MTHFR is a...
      Listen now
    Recommended
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png

    About

    • About Us
    • CME Center
    • FAQ
    • Contact Us

    Shop Online

    • Newsletters
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN Self-Assessment Courses

    Newsletters

    • The Carlat Psychiatry Report
    • The Carlat Child Psychiatry Report
    • The Carlat Addiction Treatment Report
    • The Carlat Hospital Psychiatry Report
    • The Carlat Geriatric Psychiatry Report
    • The Carlat Psychotherapy Report

    Contact

    carlat@thecarlatreport.com

    866-348-9279

    PO Box 626, Newburyport MA 01950

    Follow Us

    Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

    © 2025 Carlat Publishing, LLC and Affiliates, All Rights Reserved.